All storiesCancer

More active mitochondria may help chronic myeloid leukemia cells withstand treatment

Researchers have found that mitochondrial activity in chronic myeloid leukemia (CML) cells might influence how well patients respond to treatment, suggesting a potential target to improve therapy effectiveness.

NeoMD Editors · 2026-10-13 · 02:39 AM EDT

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

Researchers found that chronic myeloid leukemia (CML) cells with more active mitochondria may better survive treatment, indicating mitochondrial function might affect therapy response.
The findings are based on laboratory studies showing a correlation between mitochondrial activity in CML cells and their endurance of treatment, but clinical relevance is not yet established.
Further research, including clinical trials, is needed to determine if targeting mitochondrial function can safely improve treatment outcomes for CML patients.

Editorial illustration for More active mitochondria may help chronic myeloid leukemia cells withstand treatment — AI-generated editorial illustration.

What the Research Found

Scientists from Adelaide and Singapore have discovered new insights into chronic myeloid leukemia (CML), a type of blood cancer. Their research indicates that cancer cells with more active mitochondria—the energy-producing parts of cells—may better survive treatment. This suggests mitochondrial function could be affecting response to therapy in CML patients.

Evidence Behind the Finding

The research focused on the mitochondria within CML cells, observing that variations in mitochondrial activity correlated with how well the cancer cells endured treatments. While the detailed experimental methods and participant information are not provided, these findings come from molecular and cellular studies examining cancer cell behavior.

Supporting editorial illustration for More active mitochondria may help chronic myeloid leukemia cells withstand treatment — AI-generated editorial illustration.

Limitations and Unknowns

At this stage, the evidence is from laboratory research rather than clinical trials involving patients. It is not yet clear whether directly targeting mitochondrial function can safely improve treatment outcomes in CML. The research establishes a correlation between mitochondrial activity and treatment resistance but does not prove causation or confirm that modifying mitochondria will benefit patients. More studies, including clinical investigations, are needed to understand how these findings might translate into new therapies.

Possible Implications

If future research confirms these observations, targeting mitochondrial function in CML cells may become a strategy to enhance the effectiveness of existing treatments. This could lead to better responses for patients whose cancer currently withstands therapy. However, the development of such approaches is likely a long-term goal requiring extensive testing for safety and effectiveness.

Source: Medical Xpress